Metastatic (Tesaro IIP Kim)

Phase II study of niraparib in patients with advanced melanoma with genetic homologous recombination (HR) mutation / alteration

Location: CPMC (San Francisco)

Please contact ClinicalResearch@sutterhealth.org for more details about study Tesaro IIP Kim

Eligibility Requirements

 Patients with advanced melanoma with genetic homologous recombination (HR) mutation/ alteration including:

·   mutation/ deletion in ARID1A/B, ARID2, ATM, ATR, BARD1, BRCA1/2, BAP1, BRIP1, CHEK2, FANCD2, MRN11A, RAD50, RAD51, RAD54B   (and/or other mutations deemed by the study team to be HR deficient); the genetic analysis for somatic mutations must be performed in a lab that has obtained CLIA certification. 

Principal Investigator

Kevin Kim, MD

Start Date

March 19, 2019